Get in Touch

COVAXX to Present Data on COVID-19 Vaccine Candidate UB-612 at Two Virtual Scientific Conferences

HAUPPAUGE, NY (October 20, 2020) – COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced that Chief Scientific Officer Dr. Farshad Guirakhoo will present new data on COVAXX’s vaccine candidate, UB-612, and participate in panel discussions at the following conferences:

World Vaccine Congress Europe

Session title:” Vaccine Technologies to Tackle COVID-19 Presentations” Session date: Wednesday, October 21, at 9:10 am EDT 

Festival of Biologics: World Immunotherapy Congress

Session title: “UB-612: A multitope peptide-based vaccine entering clinic” Session date: Monday, November 2, at 10:40 am EST

Session title: “Progress on COVID-19 vaccine development programs”

Session date: Monday, November 2, at 11:40 pm EST

World Vaccine Congress Europe is a multi-faceted virtual conference experience with industry-leading speakers and exhibitors that highlights disruptors and visionary industry leaders from the biopharma industry.

Festival of Biologics: World Immunotherapy Congress focuses on research and development of antibody-based therapeutics and related biologics while encouraging conversation across the entire industry to address complex challenges that the biologics industry is currently facing.

COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. The investigational vaccine is designed to mimic natural biology and preclinical studies have shown very high immunogenicity (e.g. induction of high levels of neutralizing antibodies against SARS-CoV-2). The technology platform has been successful in commercializing blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date.

COVAXX is currently conducting Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase1/2 trials in the United States, upon regulatory approval. Last month, COVAXX announced an agreement with Dasa, the largest diagnostic medical company in Brazil to conduct a large-scale human efficacy clinical trial in Brazil.


About COVAXX.

COVAXX is developing a Multitope Peptide-Based Vaccine for COVID-19. The investigational vaccine has shown promising preclinical safety and efficacy data and is based on a commercially proven, scalable vaccine platform. The mission of COVAXX is to safeguard lives by tackling the global COVID-19 pandemic using cost-effective, scalable and proven science-based solutions delivered to the world.

COVAXX is a subsidiary of United Biomedical Inc (UBI), founded in 1985 and headquartered in New York. UBI has established a long legacy as a scientific trailblazer creating technological firsts, including the manufacture and commercialization of more than 100 million antibody blood diagnostic tests and 5 billion vaccine doses against virulent diseases in animal health. With exclusive access to UBI's core technology platforms, COVAXX can operate worldwide in developing and commercializing high precision antibody tests and developing a COVID-19 vaccine that together would form a unique DIVI system (Differentiating Infected from Vaccinated Individuals) that would be of high demand once vaccination programs are on their way worldwide in the not too distant future.

For more information, visit www.covaxx.com and follow us on social media.

Key Takeaways
  • COVAXX's CSO, Dr. Farshad Guirakhoo, to present data at World Vaccine Congress Europe on October 21, 2020
  • COVAXX's CSO, Dr. Farshad Guirakhoo, to present data at Festival of Biologics: World Immunotherapy Congress on November 2, 2020
Related Bios
Farshad Guirakhoo, PhD
Chief Scientific Officer
View Full Bio>>
Contacts
Diane Murphy
diane@covaxx.com
(310) 658.8756
David Schull
David.Schull@russopartnersllc.com
(212) 845-4271
Media Relations
Ignacio Guerrero-Ros
ignacio.guerrero-ros@russopartnersllc.com
6462496817
Media Relations